PrommerE. Oxymorphone: A review. Support Care Cancer, 2006; 14:109–115.
2.
AdamsMP, AhdiehH. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs Res Dev, 2005; 6:91–99.
3.
AdamsMP, AhdiehH. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study. Pharmacother, 2004; 24:468–476.
4.
LeeMA, LengMF, CooperRM. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Palliat Med, 2005; 19:259–260.
5.
AdamsMP, PieniazszekHF, GammaitoniAR, AhdiehH. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol, 2005; 45:337–345.
HaleME, AhdiehH, MaT, RauckR. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. J Pain, 2007; 8:175–184.
9.
HaleME, DvergstenC, GimbelJ. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain, 2005; 6:21–28.
10.
KivitzA, MaC, AhdiehH, GalerBS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther, 2006; 28:352–364.
11.
MatsumotoAK, BabulN, AhdiehH. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physicial function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med, 2005; 6:357–366.
12.
McIlwainH, AhdiehH. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain. A one-year study. Am J Ther, 2005; 12:106–112.
13.
GimbelJS, AhdiehH. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg, 2004; 99:1472–1477.
14.
GimbelJS, WalkerD, MaT, AhdiehH. Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: Results of a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehab, 2005; 86:2284–2289.
15.
GabrailNY, DvergstenC, AhdiehH. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin, 2004; 20:911–918.
16.
SloanP, SlatkinN, AhdiehH. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer, 2005; 13:57–65.
17.
SlatkinN, FraileyA, MaT, AhdiehH. Oxymorphone extended-release offers long-term safety, effectiveness, and dose stabilization in cancer pain: Results from a one-year interim report [Abstract]J Pain, 2003; 4,Suppl 1:84.
